This biotech is forecasted to grow at a 25% rate next year.
Inovio Pharmaceuticals, Inc. (INO)
From Cotton’s Technically Speaking
Inovio Pharmaceuticals, Inc. (INO) is a late-stage biotechnology company that focuses on the discovery, development and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases.
The diseases targeted in various clinical trials include: Human papillomavirus-caused pre-cancers and cancers and glioblastoma multiforme, and the following viruses: Hepatitis B & C, AIDS, Ebola and Zika.
Its partners and collaborators include Regeneron Pharmaceuticals, the National Institutes of Health, Genentech, and many more.
We consider this a speculative stock. We bought the stock at $3.62 on December 26, 2019. Roth Capital initiated coverage on December 19 with a ‘Buy’ rating and a $13 price target.
Joseph Cotton, Cotton’s Technically Speaking, www.cottonstocks.net, 727-289-4436, December 31, 2019